3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
72
Breast Neoplasms
9
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Prostate Cancer Metastatic
3
Metastatic Castration Resistant Prostate Cancer
3
Bulbo-Spinal Atrophy, X-Linked
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Metastatic Hormone Sensitive Prostate Cancer
2
Melanoma
2
mCRPC
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Seizures
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Pancreatic Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
pembrolizumab
3
napabucasin
3
Paclitaxel
3
Irinotecan
3
selpercatinib
2
pralsetinib
2
patritumab
2
Standard of Care
2
Pemetrexed
2
Nivolumab
2
Fluorouracil
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Ascorbic Acid
2
Albumin-Bound Paclitaxel
2
valrubicin
1
sotorasib
1
ribociclib
1
relatlimab
1
pamiparib
1
osimertinib
1
ipatasertib
1
durvalumab
1
dostarlimab
1
cobimetinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms by Site
×
enzalutamide
×
Clear all
No trials found.